


## LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease

Maria Kedariti<sup>1</sup>, Emanuele Frattini<sup>2,3</sup>, Pascale Baden<sup>4</sup>, Susanna Cogo<sup>5,10</sup>, Laura Civiero<sup>5,11,12</sup>, Elena Ziviani<sup>5</sup>, Gianluca Zilio<sup>5</sup>, Federico Bertoli<sup>4</sup>, Massimo Aureli<sup>6</sup>, Alice Kaganovich<sup>5,7</sup>, Mark R Cookson<sup>7</sup>, Leonidas Stefanis<sup>1,8</sup>, Matthew Surface<sup>9</sup>, Michela Deleidi<sup>4</sup>, Alessio Di Fonzo<sup>2,3</sup>, Roy N. Alcalay<sup>9</sup>, Hardy Rideout<sup>1,CA</sup>, Elisa Greggio<sup>5,12,CA</sup> and Nicoletta Plotegher<sup>5,CA</sup>



### Supplementary Figure 1

GCase activity assessed with the in-cell method from Benz 2021 protocol. No differences were observed between genotypes or treatments (two-way ANOVA, Tukey's multiple comparisons test). Each dot represents one subject and the value is the average of 2 biological replicates each with 3 technical replicates for DMSO and one biological replicate with 3 technical replicates for 10 nM and 100 nM MLI-2.